Selection Bioscience LLC

Other

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unitris Biopharma Co., Ltd.

Shanghai Best-link Bioscience

Zhang, Fuyao

Fuyao Zhang

Huoming Li

Xiaoming Shen

Piaoyang Sun

Dong Wei

Weijun Fang

Yuxiang Shao

Xinning Zhang

Xianjie Chen

Hua Sun

Hongshun Yuan

Gaoqiang Hu

The present invention relates to an amphiphilic block copolymer represented by formula I, a preparation method thereof, and a nanomicelle drug delivery system formed from the copolymer and a poorly soluble drug. The amphiphilic block copolymer includes a hydrophilic chain segment, a hydrophobic chain segment, and a linker for linking the hydrophilic chain segment to the hydrophobic chain segment. The linker contains an unsaturated structure, which can enhance the interaction between the poorly soluble drug and the copolymer to improve the drug loading ability and stability of the nanomicelle. The invention also relates to a nanomicelle drug-loading system, a preparation method thereof, and the use of the nanomicelle drug-loading system for preparing medicines for treating tumors, inflammation, diabetes, central nervous system diseases, cardiovascular diseases, and psychological disorders. 

Amphiphilic block copolymer, preparation method thereof and nanomicelle drug-loading system

Disclosed are an intermediate of Eribulin and a preparation method therefor. In particular, disclosed are compounds as represented by formula II, formula III and formula V and a preparation method therefor. Ar is Calkyl substituted, alkyloxy substituted or unsubstituted aryl; Rand Ris an acetal protecting group or a thioacetal protecting group; Ris hydrogen or a hydroxyl protecting group; and X is halogen or a leaving group. The preparation method therefor has the advantages of mild reaction conditions, high selectivity, easy purification, low synthesis cost and the like, being suitable for large scale production. 

Intermediate of eribulin and preparation method therefor

The present invention provides a compound as shown in general formulas (I) or (II) and a pharmaceutically acceptable salt, an isomer or a mixture form thereof, a solvate, a polymorph, a stable isotope derivative, or a prodrug of the same. The compound of the present invention has CDK kinase inhibitory activity and can be used in treating a disease related to CDK kinase, such as a cancer. 

Compound with kinase inhibitory activity and preparation method and use thereof

Disclosed are a compound as shown in general formula I, a pharmaceutically acceptable salt, an isomer or a mixture thereof, and a solvate, a polymorph, a stable isotope derivative or a prodrug thereof. The compound of the present disclosure has comparatively strong PARP inhibitory activity and can be used for treating diseases associated with PARP, such as cancers and inflammatory diseases. 

Poly(ADP-ribose) polymerase inhibitor, preparation method and use

The invention relates to a tenofovir prodrug and pharmaceutical uses thereof. In particular, the invention relates to a compound as shown in general formula (I): and its isomer, pharmaceutically acceptable salt, hydrate or solvate, as well as their uses in preparing drugs for treating viral infectious diseases, especially HIV infection, hepatitis B, or diseases caused by hepatitis B virus, wherein the definition of each substituent in the general formula (I) is as defined in the specification.

Tenofovir prodrug and pharmaceutical uses thereof

The present invention relates to an intermediate, as represented by formula (I), for synthesizing caspofungin, and a preparation method thereof. The intermediate enables efficient preparation of caspofungin. 

Intermediate for synthesizing caspofungin and preparation method thereof

Growing community of inventors

Shanghai, China

Fuyao Zhang